Mostly Markets
Subscribe
Stocks/Health Care/Health Care Supplies

West Pharmaceutical ServicesWST

Health Care Supplies · Exton, Pennsylvania · In the S&P 500
Solid businessPricier than peers
$412.62−0.97%After hours: $412.62 (0.00%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 44.9% over 1 year
West Pharmaceutical Services over 1 yearDaily close, $, to 30 Oct 2026
$300$400Nov2026MarMayJulSep$412.62$300NovMarJul$412.62
Source: Nasdaq daily closes
Market value$29.04B
Price to earnings46.3x
Forward P/E44.3x
Dividend yield0.25%
Year to date+50.0%
One year+44.9%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$230.95$416.67

Quality and valuation

How West Pharmaceutical Services compares with other health care stocks. A description, not a recommendation.

West Pharmaceutical Services and 5 health care supplies peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: pricier than most

An average business among health care companies, priced above most of them.

West Pharmaceutical Services trades at 44.3 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +12.6% vs +7.8%
  • Keeps less of each sale (gross margin): 37.6% vs 65.3%
  • More profitable (operating margin): 23.0% vs 13.3%
  • Turns less of its sales into cash: 13.3% vs 15.9%
WST trades at 44.3x forward earnings, above the sector medianForward p/e, Health Care Supplies peers
NVS17.0xAZN17.5xMRK18.1xUNH18.9xABBV19.6xJNJ25.1xLLY36.3xWST44.3xSector median 19.1xNVS17.0xAZN17.5xMRK18.1xUNH18.9xABBV19.6xJNJ25.1xLLY36.3xWST44.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 46.3x earnings, WST is pricier than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
30x40x50xAverage 40.7x2025202646.3x30x40x50xAverage 40.7x2025202646.3x
Source: Nasdaq prices; SEC filings

Financials

From West Pharmaceutical Services's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 8.7% from a year earlierQuarterly revenue, $m, latest Q3 ’26
$0m$250m$500m$750mQ4 ’24Q2 ’25Q4 ’25$874mQ3 ’26$0m$500mQ4 ’24Q2 ’25Q4 ’25$874mQ3 ’26
Source: SEC filings
Growth slowed to +8.7% last quarterRevenue growth, year on year, %
0%10%20%Q4 ’24Q2 ’25Q4 ’258.7%Q3 ’260%10%20%Q4 ’24Q2 ’25Q4 ’258.7%Q3 ’26
Source: SEC filings
Operating margin was 30.6% last quarterOperating income as a share of revenue, %
0%10%20%30%Q4 ’24Q2 ’25Q4 ’2530.6%Q3 ’260%20%Q4 ’24Q2 ’25Q4 ’2530.6%Q3 ’26
Source: SEC filings
Free cash flow was $453 million over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$50m$100m$150mQ4 ’24Q2 ’25Q4 ’25$150mQ3 ’26$0m$100mQ4 ’24Q2 ’25Q4 ’25$150mQ3 ’26
Source: SEC filings
Last 12 monthsWSTSector median
Revenue growth+12.6%+7.8%
Gross margin37.6%65.3%
Operating margin23.0%13.3%
Free cash flow margin13.3%15.9%
Price to earnings46.3x30.2x

Stories on West Pharmaceutical Services

We haven't written about West Pharmaceutical Services yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Health Care Supplies, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
ABBVAbbVie$294.89+1.41%+29.1%$521B
MRKMerck$149.52+2.18%+42.0%$369B
UNHUnitedHealth$406.97−0.96%+23.3%$365B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B